Steven Leonard Chapman

Then-CEO Steven Leonard Chapman sold 41,124 shares for $9,089,776.37 on 2026-06-04 via pre-arranged 10b5-1 plan.

Steven Leonard Chapman, who was CEO at the time, executed 14 separate sales totaling 41,124 shares for $9,089,776.37 on 2026-06-04, reducing his holdings from 149,867 shares to 108,743 shares. The transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on 2023-12-11, meaning the sales were scheduled rather than discretionary. This blended average price of $221.03 compares to the current price of $215.31, placing the transaction price above current levels. The company generated $696.6M in revenue during the latest quarter with negative annual net income of $-85.1M, suggesting profitability challenges despite 35.9% revenue growth year-over-year; Chapman's prior sales at NTRA have yielded subsequent 90-day returns ranging from +8.7% to +11.6%, indicating his earlier sales preceded periods of stock appreciation.

CEO Chapman sells 5,838 shares for $1,191,774.74 at blended $204.14; stock now -23.4% from 52-week high

Chapman Steven Leonard, CEO and President, executed two separate sales totaling 5,838 shares for $1,191,774.74 at an average price of $204.14 on 2026-04-27. The current stock price of $194.75 sits -23.4% from the 52-week high of $254.40, suggesting the CEO sold well above current levels. His post-transaction holdings remain substantial at 150,769 shares, and this sale represents a modest -3.7% reduction of his prior stake. The recent price momentum shows mixed signals: the stock is up 4.2% over the last 30 days but down -15.9% over the prior 90 days, reflecting volatility in a growth-stage biotech company that posted $592.2M in revenue but remains unprofitable with -$87.5M in net income.

CEO Chapman sold 5,623 NTRA shares at $204.13; stock now at $196.61, -22.7% from 52-week high.

CEO Chapman Steven Leonard sold 5,623 shares at $204.13 on 2026-03-10, reducing his stake by 3.5% while retaining substantial holdings of 156,607 shares. The sale occurred near but not at the stock's 52-week peak of $254.40; NTRA has declined -22.7% from that high and is down -6.6% over 30 days and -14.9% over 90 days since the transaction date. Chapman's cross-ticker track record shows a 75.00% well-timed rate on 20 prior sells (average 90-day return -5.3%), but his same-ticker history at NTRA is less conclusive—he completed three additional sales on 2026-03-02 (outcomes not yet measurable) and two earlier sales in February with mixed 30-day results (-14.6% and -13.0%) before 90-day outcomes could be assessed. The company remains unprofitable on a full-year basis despite strong 35.9% annual revenue growth and a substantial $27.9B market cap, creating tension between momentum and fundamentals.

CEO Steven Leonard sold 3,950 shares of NTRA for $790,094.99 across 3 transactions on 2026-03-02

Steven Leonard, CEO and President of Natera, Inc., executed 3 separate sales totaling 3,950 shares for $790,094.99 at an average price of $200.02. His post-transaction holdings of 156,607 shares represent a 2.5% reduction from his prior position. The current stock price of $207.04 stands 18.6% below the 52-week high of $254.40, and the stock has declined 10.4% over the past 30 days and 13.1% over the past 90 days. While Leonard's cross-ticker track record shows a 90-day well-timed rate of 42.86% on 20 prior open-market sells, his trading pattern at NTRA specifically shows 5 prior sells (all recent, concentrated in early February 2026) with no measurable outcome history yet available. The company remains unprofitable with a net loss of $87,544,000.00 in its latest quarter despite revenue growth of 35.9% year-over-year, pointing to ongoing margin challenges in a high-growth biotech context.

NTRA CEO Chapman sold 90,024 shares for $20.8M (Feb 2–3), reducing stake by 42.2% to 123.2K shares held.

Chapman Steven Leonard, CEO and President, executed 7 separate sales over two days totaling 90,024 shares for $20,770,418.93 at a blended average price of $230.72. This represents a 42.2% reduction in his post-transaction holdings, from 213.2K shares down to 123.2K. The current stock price of $205.61 stands 19.2% below the 52-week high and 10.9% below Chapman's execution prices, yet his cross-ticker historical track record shows a 0.00% well-timed rate on sells—suggesting prior sales have been followed by stock rallies rather than declines. At the company level, Natera remains unprofitable ($-87.5M net income on $592.2M quarterly revenue) despite 56.8% annual revenue growth, a mismatch between scale and profitability that creates uncertainty about sustainable valuation support going forward.

CEO Chapman Steven Leonard sold 5,970 shares of NTRA for $1,425,506.12 across two consecutive days (Jan 27-28) near 52-week highs

CEO Chapman Steven Leonard executed two separate sales totaling 5,970 shares for $1,425,506.12 on 2026-01-27 and 2026-01-28 at a blended average price of $238.78, occurring within 3% of the 52-week high of $254.40. His post-transaction holdings remain substantial at 213,180 shares, representing only a 2.7% reduction. The company operates with significant losses (net income of $-87,544,000.00 on revenue of $592,183,000.00) despite strong annual growth of 56.8%, creating inherent tension between growth trajectory and profitability. The CEO's cross-ticker track record shows 20 prior sales with a 0.00% well-timed rate (stock rose 39.1% on average in the 90 days following those prior sales), suggesting his recent NTRA sales warrant monitoring for directional signals, though current context shows the stock up 0.6% over 30 days and up 16.4% over 90 days post-transaction announcement.

CEO Chapman Steven Leonard sold 73,522 shares for $17.3M at $234.74 avg; -25.1% of holdings in 2 txns

Chapman Steven Leonard, CEO and President of Natera, Inc., executed 2 separate sales totaling 73,522 shares for $17,258,852.59 at a blended average price of $234.74, reducing his holdings by 25.1% from 292,672 to 219,150 shares. The company trades 4.5% below its 52-week high of $254.40 at $242.91 current price, having gained 26.2% over the past 90 days. However, at NTRA specifically, Chapman's 5 prior trades show recent 30-day declines: the 3 December 2025 sales posted -3.8%, -3.4%, and -4.3% 30-day returns, suggesting his recent sales at this ticker have not preceded further gains. The company is unprofitable with net income of $-87,544,000.00 despite strong 56.8% annual revenue growth to $592,183,000.00, a context where liquidity decisions by insiders merit attention given the valuation asymmetry between market cap ($33.5B) and profitability.

NTRA CEO Chapman sold 3,848 shares for $881.5K at avg $229.08 on 2026-01-02; now at $248.74 (+8.6% above sale price).

Chapman Steven Leonard (CEO AND PRESIDENT) executed 2 separate sales totaling 3,848 shares for $881,481.72 on 2026-01-02, reducing his holdings by 2.7% to 136,568 shares. The sales occurred at an average price of $229.08, while the stock now trades at $248.74—meaning the CEO sold below current levels despite the stock's strong 90-day rally of +44.5%. Against his cross-ticker track record (20 prior sells with an 8.33% well-timed rate), his prior sales at NTRA have shown poor timing outcomes: recent December 2025 sales each fell 3.4%–4.3% over 30 days, though sales in November rose 19.1%–19.7% in the same window. The fundamental context shows a high-growth business ($592.2M revenue, +56.8% annual growth) with significant current losses ($-87.5M net income), suggesting profitability remains uncertain despite recent momentum.

CEO Chapman sells 4,400 NTRA shares for $1,047,501.95; stock +20.2% in 30 days post-sale.

Chapman Steven Leonard, CEO and President, executed 3 separate sales on 2025-12-01 totaling 4,400 shares for $1,047,501.95 at a blended average price of $238.07, reducing his holdings by 3.0% to 140,416 shares. The stock has rallied +20.2% in the 30 days following the sale and currently trades at $238.21, only 0.2% below its 52-week high of $238.81, indicating the sale occurred near the peak of a sharp recent advance. His prior 5 trades at NTRA have all shown positive 30-day returns (ranging from +19.1% to +23.8%), suggesting a pattern of selling into strength; however, none have yet had measurable 90-day outcomes, limiting conclusions about whether these sales represent well-timed exits. Against this backdrop, the company remains unprofitable with a full-year net loss of $-87,544,000.00, despite strong revenue growth of +56.8% year-over-year.

CEO Chapman sells 160,703 shares for $32.1M at blended $199.96, reducing stake by 52.6% in stock up 41.5% over 90 days.

Chapman Steven Leonard, CEO and President of Natera (NTRA), executed three separate sales on 2025-11-03 totaling 160,703 shares for $32,133,980.77 at a blended average price of $199.96. This represents a 52.6% reduction in his pre-transaction holdings, declining from 305,519 shares to 144,816 shares. The timing is notable: the sales occurred as NTRA stock has appreciated 41.5% over the prior 90 days and currently trades near its 52-week high (0.4% below the $198.93 peak). The company reported $546.6M in quarterly revenue with strong 56.8% annual growth, but remains unprofitable with $-100.9M in net income for its most recent full fiscal year. While Chapman's cross-ticker track record shows a 40.00% well-timed sell rate historically, his five prior sales at NTRA itself have uniformly posted positive 30-day returns (23.2% to 25.2%), with none yet showing measurable 90-day outcomes. The significant magnitude of this liquidation at or near peak valuations warrants investor scrutiny of the underlying motivation and company health trajectory.